Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD Free cash flow yield

Free cash flow yield at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
5%+0.6pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-15.2%-4.4pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-13.1%+0.4pp
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
19.2%+13.6pp
Vera Therapeutics logo
Vera TherapeuticsVERA
-10.2%0.0pp
HRO
HarrowHROW
——

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

free cash flow/market cap=-6.4%

Based on trailing twelve months.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's free cash flow yield?
Kodiak Sciences Inc (KOD) reported free cash flow yield of -6.4% in Q1 2026.
How has Kodiak Sciences Inc's free cash flow yield changed year-over-year?
Kodiak Sciences Inc's free cash flow yield increased by 91.3% year-over-year, from -72.8% to -6.4%.
What is the long-term trend for Kodiak Sciences Inc's free cash flow yield?
Over 5 years (2020 to 2025), Kodiak Sciences Inc's free cash flow yield has grown at a 47.4% compound annual growth rate (CAGR), from -1.1% to -8%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.